Use of patient-reported outcomes (PRO) data to complement exposure–response analysis in early clinical cancer drug development

BACKGROUND: This proof-of-concept retrospective case study investigated whether patient-reported outcomes (PRO) instruments, designed to capture symptomatic adverse event data, could identity a known exposure–response (ER) relationship for safety characterized in an original FDA analysis of an appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Huiming, Booth, Brian P., Wang, Yaning, Fan, Chunling, Bhatnagar, Vishal, Kluetz, Paul, Fourie Zirkelbach, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656371/
https://www.ncbi.nlm.nih.gov/pubmed/37975967
http://dx.doi.org/10.1186/s41687-023-00651-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656371/
https://www.ncbi.nlm.nih.gov/pubmed/37975967
http://dx.doi.org/10.1186/s41687-023-00651-2

Ejemplares similares